ENDRA Life Sciences (NDRA) Fundamentals 2026 — Revenue Analysis | SniperIQ
ENDRA Life Sciences (NDRA) is a US-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of $4M, trading at $5.41 on the NASDAQ. This SniperIQ fundamentals page covers ENDRA Life Sciences's valuation, profitability (net margin 0.0%), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is ENDRA Life Sciences's market cap?
ENDRA Life Sciences (NDRA) has a market capitalization of approximately $4M, trading at $5.41 on the NASDAQ. Market cap moves with the live share price.
What is ENDRA Life Sciences's P/E ratio?
ENDRA Life Sciences's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is ENDRA Life Sciences?
ENDRA Life Sciences runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does ENDRA Life Sciences pay a dividend?
ENDRA Life Sciences does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is ENDRA Life Sciences financially healthy?
ENDRA Life Sciences carries a debt-to-equity ratio of 0.26x and a current ratio of 0.64x, with a market beta of -0.05. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is ENDRA Life Sciences a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For ENDRA Life Sciences (NDRA) the key facts are: market cap $4M, 52-week range 2.96-9.85. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track ENDRA Life Sciences's full fundamentals live
Get ENDRA Life Sciences's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.